{"created":"2021-03-01T06:38:46.962316+00:00","id":30461,"links":{},"metadata":{"_buckets":{"deposit":"8646c22a-4d69-48d4-9591-6b10408a0a8c"},"_deposit":{"id":"30461","owners":[],"pid":{"revision_id":0,"type":"depid","value":"30461"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:00030461","sets":["499:500:501"]},"author_link":["101312","101313","101314","101315","101316","101317","101318","101319","101320","101321","101322"],"item_10_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-05","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"280.e4","bibliographicPageStart":"273","bibliographicVolumeNumber":"21","bibliographic_titles":[{"bibliographic_title":"Clinical Lung Cancer","bibliographic_titleLang":"en"}]}]},"item_10_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Oncogenic EGFR signaling has been shown to upregulate vascular endothelial growth factor A (VEGFA) expression involved in tumor angiogenesis. However, the clinical benefits of bevacizumab plus cytotoxic chemotherapy for EGFR mutation–positive patients remain unclear. This study aimed to investigate VEGFA messenger RNA expression in patients with EGFR mutation, and to further compare the efficacy of bevacizumab combined with platinum-based chemotherapy between EGFR-mutant and wild-type patients. Patients and Methods: Gene expression of various proangiogenic factors was analyzed in nonsquamous, non–small-cell lung cancer (NSCLC) patients using The Cancer Genome Atlas dataset. Additionally, clinical data of patients receiving carboplatin and pemetrexed (CPem; n = 104) or bevacizumab plus CPem (BevCPem; n = 55) at Nagoya University hospital were retrospectively assessed for progression-free survival and best overall response rate (ORR). Results: Among various proangiogenic factors, only VEGFA expression was significantly higher in patients with advanced nonsquamous NSCLC with EGFR mutation compared to wild-type patients (P = .0476). Progression-free survival in the BevCPem group was significantly longer in patients with EGFR mutation than in wild-type patients (10.5 vs. 6.6 months; Wilcoxon P = .0278), while the difference in the CPem group was not significant (6.6 vs. 4.5 months; Wilcoxon P = .1822). The ORRs in the BevCPem group were 54.5% and 36.4% for EGFR-mutant and wild-type patients, respectively, and the ORRs in the CPem group were 35.5% and 28.8 % in EGFR-mutant and wild-type patients, respectively. Conclusion: VEGFA messenger RNA expression was significantly increased in advanced nonsquamous NSCLC harboring EGFR mutation, and BevCPem provided better clinical benefits to patients with EGFR mutation than wild-type carriers.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"ファイル公開日: 2021/05/01","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier","subitem_publisher_language":"en"}]},"item_10_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.cllc.2020.01.011","subitem_relation_type_select":"DOI"}}]},"item_10_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/","subitem_rights_language":"en"}]},"item_10_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"author"}]},"item_10_source_id_61":{"attribute_name":"ISSN（print）","attribute_value_mlt":[{"subitem_source_identifier":"1525-7304","subitem_source_identifier_type":"PISSN"}]},"item_1615787544753":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tanaka, Ichidai","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101312","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Morise, Masahiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101313","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Miyazawa, Ayako","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101314","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kodama, Yuta","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101315","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tamiya, Yutaro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101316","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Gen, Soei","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101317","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsui, Akira","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101318","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hase, Tetsunari","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101319","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hashimoto, Naozumi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101320","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sato, Mitsuo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101321","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Yoshinori","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"101322","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-05-01"}],"displaytype":"detail","filename":"article.pdf","filesize":[{"value":"686.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"article","objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/30461/files/article.pdf"},"version_id":"c5ec5105-bb53-4b47-a34d-955c33cda22b"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Carboplatin","subitem_subject_scheme":"Other"},{"subitem_subject":"Epidermal growth factor receptor","subitem_subject_scheme":"Other"},{"subitem_subject":"NSCLC","subitem_subject_scheme":"Other"},{"subitem_subject":"Pemetrexed","subitem_subject_scheme":"Other"},{"subitem_subject":"VEGFA","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation","subitem_title_language":"en"}]},"item_type_id":"10","owner":"1","path":["501"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-09-17"},"publish_date":"2020-09-17","publish_status":"0","recid":"30461","relation_version_is_last":true,"title":["Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-01-16T04:23:56.490894+00:00"}